Replies to post #64463 on Biotech Values

[DewDiligence]

I think the serious negotiations will begin at $100/sh. There won’t even be a shareholder vote for anything less, IMO.

[DewDiligence]

The evaluation by IB’s is Roche's “nuclear option.”

The IB’s might end up establishing a higher price than Roche can negotiate on its own. Moreover, the nuclear option would ruin the goodwill Roche has worked so hard to establish with DNA’s personnel.



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”